The above is a presentation part of the "Glucagon receptor/GLP-1 receptor dual agonism in people with obesity and type 2 diabetes: insights from the SYNCHRONIZE Phase 3 studies of survodutide" Symposium at EASD 2026.
No takes yet. Share an insight, caveat, or question.
Sean Wharton (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: